SU
Suraksha Diagnostic Ltd (SURAKSHA)
₹311.50
Mkt cap
₹1,841 Cr
P/E ratio
44.00
P/B
5.88
Div yield
0.14%
ROE
14.20%
ROCE
17.30%
EPS (TTM)
₹7.08
Book value
₹53
52W range
224–384
Sector
Healthcare
Price history
Previous close
Incorporated in 2005, Suraksha Diagnostic offers an integrated pathology, radiology testing, and medical consultancy services solution. [1]
NSE SURAKSHABSE 544293
Health check
Mixed
ValuationFair
ProfitabilityAverage
GrowthModerate
TechnicalsNeutral
52-week range
−18.88% from high₹312
₹224+39.00% from low₹384
Current
₹311.50
Prev close
₹329.90
Day
−5.58%
Price performance
1D
−5.43%
1W
−8.69%
1M
+7.98%
3M
+2.24%
6M
−2.53%
1Y
+0.61%
YTD
+12.60%
Financials
Revenue, profit & margin
P/E ratio
44.0×
SURAKSHA is 16% above the sector median of 38.0×
SURAKSHA44.0×
Sector median38.0×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 60 | 52 | 55 | 61 | 67 | 60 | 65 | 73 | 79 | 78 | 81 | 88 | 99 | |
| YoY Sales growth | +11% | +15% | +18% | +20% | +18% | +31% | +25% | +21% | +26% | |||||
| Expenses | 39 | 36 | 36 | 40 | 44 | 41 | 46 | 49 | 55 | 55 | 57 | 57 | 64 | |
| Operating Profit | 21 | 15 | 19 | 21 | 23 | 18 | 19 | 24 | 24 | 23 | 24 | 30 | 35 | |
| OPM % | 35% | 30% | 35% | 34% | 35% | 31% | 29% | 33% | 31% | 30% | 30% | 35% | 35% | |
| Other Income | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | |
| Interest | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 4 | 4 | 5 | |
| Depreciation | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 10 | 11 | 11 | 11 | 13 | |
| Profit before tax | 11 | 6 | 9 | 11 | 14 | 8 | 9 | 12 | 12 | 10 | 10 | 17 | 19 | |
| Tax % | 24% | 27% | 32% | 27% | 26% | 26% | 22% | 26% | 27% | 28% | 38% | 22% | 21% | |
| Net Profit | 8 | 5 | 6 | 8 | 10 | 6 | 7 | 9 | 9 | 7 | 6 | 13 | 15 | |
| EPS in Rs | 1.61 | 0.89 | 1.25 | 1.52 | 1.99 | 1.18 | 1.42 | 1.80 | 1.73 | 1.44 | 1.21 | 2.50 | 2.88 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202649.10%Promoter
Promoters49.10%
FIIs13.98%0.51
DIIs21.56%1.66
Public15.37%1.17
Ownership trend
Peers
7 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Dr Lal Pathlabs | ₹1,980.20 | 54.89 | 33,237 | 0.71% | 194 | +28.75% | 874 | +19.61% | 28.00% |
| Vijaya Diagnost. | ₹1,467.40 | 74.20 | 15,114 | 0.14% | 59 | +37.41% | 255 | +26.71% | 20.53% |
| Metropolis Healt | ₹567.00 | 50.98 | 11,767 | 0.35% | 75 | +43.04% | 497 | +15.76% | 17.81% |
| Thyrocare Tech. | ₹506.95 | 46.11 | 8,079 | 1.84% | 15 | −11.56% | 271 | +25.07% | 35.38% |
| Nephrocare Health Services | ₹667.75 | 52.41 | 6,715 | 0.00% | 34 | +454.07% | 303 | +23.47% | 15.34% |
| Suraksha Diagno. | ₹353.50 | 44.02 | 1,841 | 0.14% | 15 | +66.96% | 99 | +25.84% | 17.29% |
| Krsnaa Diagnost. | ₹518.70 | 16.66 | 1,683 | 0.39% | 25 | +8.95% | 240 | +31.17% | 12.71% |
| Median: 16 Co. | ₹369.15 | 38.04 | 1,013 | 0.07% | 15 | +10.52% | 83 | +24.27% | 21.66% |
Filings
Annual reports2
Concall transcripts21
Credit ratings1
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 13 Nov - Audio recording of November 13, 2026 earnings call for Q2 and H1 FY27 is now available.Announcement under Regulation 30 (LODR)-Investor Presentation 12 Nov - Investor Presentation for Quarter and Half Year ended 30 September 2026 Q2 FY 2026-27Announcement under Regulation 30 (LODR)-Press Release / Media Release 12 Nov - Suraksha issued corrigendum to Q2/H1 FY27 results; corrected tests, patients and revenue metrics.Clarification Regarding Non-Publication Of Newspaper Advertisement Under Regulation 47 Of SEBI (LODR) Regulations, 2015 12 NovCorrigendum To The Press Release -Interview Published In The Times Of India Dated November 11, 2026, Regarding Financial Performance For The Quarter And Half Year Ended September 30, 2026. 11 Nov - Corrigendum revises headline to total income over ₹100 crore and Q2 net profit to ₹15 crore.



